#1 Clinical Trials Search in Europe

Nimodipine

Nimodipine is a calcium channel blocker that has been the subject of several clinical trials investigating its potential benefits in various neurological conditions. This article explores the use of nimodipine in clinical trials, focusing on its applications in subarachnoid hemorrhage, cerebral vasospasm, and other neurological disorders. We’ll examine the different administration methods, dosages, and outcomes observed in these trials to better understand nimodipine’s therapeutic potential.

Table of Contents

What is Nimodipine?

Nimodipine is a medication that belongs to a class of drugs called calcium channel blockers. It is primarily used to treat certain conditions affecting the brain and blood vessels. Nimodipine is also known by its trade names, such as Nimotop, Nymalize, or RVG 12060[1][2].

Uses of Nimodipine

Nimodipine is used to treat various conditions, including:

  • Aneurysmal Subarachnoid Hemorrhage (aSAH): This is a type of bleeding in the brain caused by a ruptured aneurysm (a weak spot in a blood vessel that bulges and can burst). Nimodipine is used to reduce the risk of poor outcomes and delayed cerebral ischemia (reduced blood flow to the brain) in patients with this condition[3].
  • Cerebral Vasospasm: This is a narrowing of blood vessels in the brain that can occur after a subarachnoid hemorrhage. Nimodipine helps prevent and manage this condition[4].
  • Ischemic Cerebrovascular Disease: This refers to conditions where there is reduced blood flow to the brain, potentially leading to stroke. Nimodipine may be used in the treatment of these conditions[5].
  • Progranulin Mutation Carriers: Research is being conducted to explore the potential use of nimodipine in treating individuals with mutations in the progranulin gene, which is associated with certain types of dementia[6].

How Nimodipine Works

Nimodipine works by blocking calcium channels in the walls of blood vessels. This action helps to relax and widen the blood vessels, particularly in the brain. By improving blood flow to the brain, nimodipine can help prevent complications such as delayed cerebral ischemia and reduce the risk of poor outcomes in patients with subarachnoid hemorrhage[3].

The medication is believed to have neuroprotective effects, which means it may help protect brain cells from damage. It does this by reducing the amount of calcium that enters cells, which can be harmful in large amounts[3].

Administration Methods

Nimodipine can be administered in several ways, depending on the patient’s condition and the specific formulation:

  • Oral tablets or capsules: These are typically taken every 4 hours for up to 21 days[3].
  • Intravenous (IV) infusion: This method delivers the medication directly into the bloodstream through a vein[5].
  • Intra-arterial administration: In some cases, nimodipine may be delivered directly into an artery[3].
  • Intraventricular administration: This involves delivering the medication directly into the fluid-filled spaces (ventricles) of the brain[2].
  • Intracisternal administration: In this method, the medication is delivered into the cisterna magna, a space at the base of the skull filled with cerebrospinal fluid[7].

Research and Clinical Trials

Nimodipine is the subject of ongoing research to explore its potential benefits in various conditions:

  • Progranulin Insufficiency: Studies are investigating the use of nimodipine in individuals with mutations in the progranulin gene, which is associated with certain types of dementia[6].
  • Cocaine Dependence: Research is examining whether nimodipine can help reduce cravings in individuals with cocaine dependence[8].
  • Combination Therapies: Studies are exploring the use of nimodipine in combination with other medications, such as milrinone, for managing cerebral vasospasm[4].
  • New Formulations: Researchers are studying new ways to deliver nimodipine, such as EG-1962, a sustained-release formulation of nimodipine[2].

Potential Side Effects

Like all medications, nimodipine can cause side effects. Some potential side effects include:

  • Hypotension (low blood pressure): This is one of the most common side effects and can be particularly concerning in patients with brain injuries[3].
  • Bradycardia (slow heart rate)[4].
  • Headache
  • Nausea and vomiting
  • Dizziness

It’s important to note that not everyone experiences these side effects, and your healthcare provider will monitor you closely while you’re taking nimodipine.

Special Considerations

When taking nimodipine, there are several important points to keep in mind:

  • Monitoring: Your healthcare provider will likely monitor your blood pressure, heart rate, and neurological function closely while you’re taking nimodipine[9].
  • Duration of Treatment: For subarachnoid hemorrhage, nimodipine is typically given for about 21 days[3].
  • Interactions: Nimodipine can interact with other medications, so be sure to inform your healthcare provider about all medications you’re taking.
  • Pregnancy and Breastfeeding: If you’re pregnant or breastfeeding, discuss the risks and benefits of nimodipine with your healthcare provider.

Remember, nimodipine is a prescription medication that should only be taken under the guidance of a healthcare professional. Always follow your doctor’s instructions and report any unusual symptoms or side effects promptly.

Aspect Details
Primary Conditions Studied Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm, Delayed Cerebral Ischemia
Administration Routes Oral, Intravenous, Intra-arterial, Intraventricular, Intracisternal
Novel Formulations EG-1962 (Nimodipine microparticles for sustained release)
Dosage Range Varies by study; typically 60mg orally every 4 hours, or 0.5-2mg/h intravenously
Duration of Treatment Typically up to 21 days in most studies
Primary Outcome Measures Glasgow Outcome Scale, Montreal Cognitive Assessment, Cerebral Blood Flow, Incidence of Delayed Cerebral Infarction
Safety Considerations Monitoring for hypotension, bradycardia, and other cardiovascular effects
Other Conditions Explored Progranulin Mutation Carriers, Postictal Phenomena in ECT, Cocaine-Related Disorders

FAQ

  • What is the primary use of nimodipine in clinical trials? The primary use of nimodipine in clinical trials is for the treatment of aneurysmal subarachnoid hemorrhage (aSAH) and its complications, such as cerebral vasospasm and delayed cerebral ischemia. It is being studied for its potential to improve outcomes and reduce the risk of poor neurological function after aSAH.
  • How is nimodipine administered in clinical trials? In clinical trials, nimodipine is administered through various routes, including oral tablets or capsules, intravenous infusion, intra-arterial injection, and even novel methods like intraventricular or intracisternal administration of nimodipine microparticles (EG-1962).
  • What are some potential side effects of nimodipine? Some potential side effects of nimodipine observed in clinical trials include hypotension (low blood pressure), bradycardia (slow heart rate), and in some cases, systemic effects on hemodynamics. However, the severity and frequency of these side effects can vary depending on the dosage and route of administration.
  • Are there any ongoing studies comparing nimodipine to other treatments? Yes, there are ongoing studies comparing nimodipine to other treatments or novel formulations. For example, some trials are comparing standard oral nimodipine to EG-1962, a sustained-release formulation of nimodipine microparticles, for the treatment of aneurysmal subarachnoid hemorrhage.
  • What other conditions is nimodipine being studied for in clinical trials? Besides subarachnoid hemorrhage, nimodipine is being studied in clinical trials for other conditions such as traumatic subarachnoid hemorrhage, progranulin mutation carriers (related to frontotemporal dementia), and even for potential effects on postictal phenomena after electroconvulsive therapy in depression treatment.

Ongoing Clinical Trials on Nimodipine

  • Study on Stereotactic Cisternal Lavage Therapy for Patients with Aneurysmal Subarachnoid Hemorrhage Using Urokinase, Nimodipine, and a Drug Combination

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany

Glossary

  • Aneurysmal Subarachnoid Hemorrhage (aSAH): A type of stroke caused by bleeding into the space surrounding the brain, typically due to a ruptured aneurysm (a weak spot in a blood vessel wall).
  • Cerebral Vasospasm: A narrowing of blood vessels in the brain that can occur as a complication of subarachnoid hemorrhage, potentially leading to reduced blood flow and brain damage.
  • Delayed Cerebral Ischemia: A complication of subarachnoid hemorrhage where there is a reduction in blood supply to the brain, which can occur days after the initial bleeding event.
  • EG-1962: A sustained-release formulation of nimodipine microparticles designed for intraventricular or intracisternal administration in the treatment of aneurysmal subarachnoid hemorrhage.
  • Intraventricular: Referring to administration or placement within the ventricles of the brain, which are fluid-filled cavities.
  • Intracisternal: Referring to administration or placement within the cisterns, which are areas filled with cerebrospinal fluid surrounding the brain.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Glasgow Outcome Scale (GOS): A scale used to assess the outcome and degree of recovery in patients with brain injuries, ranging from death to good recovery.
  • Montreal Cognitive Assessment (MoCA): A rapid screening instrument for mild cognitive dysfunction, used to assess various cognitive domains including attention, memory, and language.

References

  1. https://clinicaltrials.gov/study/NCT04028596
  2. https://clinicaltrials.gov/study/NCT02790632
  3. https://clinicaltrials.gov/study/NCT04649398
  4. https://clinicaltrials.gov/study/NCT05131867
  5. https://clinicaltrials.gov/study/NCT03794843
  6. https://clinicaltrials.gov/study/NCT01835665
  7. https://clinicaltrials.gov/study/NCT02893826
  8. https://clinicaltrials.gov/study/NCT00000332
  9. https://clinicaltrials.gov/study/NCT02991157